最重要的兩家國(guó)際金融機(jī)構(gòu)稱,非洲需要大約120億美元才能為足夠多的人接種疫苗,,遏制新冠肺炎在非洲大陸的傳播,。
世界銀行和國(guó)際貨幣基金會(huì)的一份新報(bào)告也指出,G20國(guó)家作為全球最富有的國(guó)家,,應(yīng)將貧困國(guó)家的債務(wù)延期至年底,。
該報(bào)告稱,非洲所需的抗疫資金數(shù)額,,與參與G20債務(wù)償還暫停計(jì)劃的45個(gè)最貧窮國(guó)家已經(jīng)延長(zhǎng)還款的官方債務(wù)償還總額相同,。
而在發(fā)展中國(guó)家廣泛使用的阿斯利康疫苗遭遇了持續(xù)的障礙,這可能限制其在貧窮國(guó)家繼續(xù)推廣,。
《華爾街日?qǐng)?bào)》周二報(bào)道,,牛津大學(xué)暫停了其聯(lián)合開(kāi)發(fā)的阿斯利康疫苗在英國(guó)進(jìn)行的小樣本臨床試驗(yàn),因?yàn)樵撗芯可婕皟和颓嗌倌?,暫停原因是?dān)心血栓問(wèn)題,。
牛津大學(xué)的一位發(fā)言人告訴《華爾街日?qǐng)?bào)》,試驗(yàn)本身沒(méi)有出現(xiàn)安全問(wèn)題,,但對(duì)血栓問(wèn)題的廣泛擔(dān)憂引發(fā)了英國(guó)和歐洲進(jìn)一步的監(jiān)管審查,。
美國(guó)等富裕國(guó)家一直致力于為本國(guó)民眾接種疫苗,但公共衛(wèi)生官員警告說(shuō),,在發(fā)展中國(guó)家為大多數(shù)公民接種疫苗之前,,疫情仍將繼續(xù)。
世界衛(wèi)生組織稱,,非洲國(guó)家接種新冠肺炎疫苗的時(shí)間比世界其他地區(qū)晚得多,,而且數(shù)量有限。目前非洲只有不到10家疫苗制造商,,僅分布在非洲大陸54個(gè)國(guó)家中的5個(gè):埃及,、摩洛哥、塞內(nèi)加爾,、南非和突尼斯,。
許多非洲國(guó)家已簽署協(xié)議,接受由全球疫苗免疫聯(lián)盟Gavi和世衛(wèi)組織領(lǐng)導(dǎo)的新冠肺炎疫苗實(shí)施計(jì)劃(Covax)提供的疫苗,。截至公布之日,,該計(jì)劃已向簽署了項(xiàng)目的90個(gè)發(fā)展中國(guó)家運(yùn)送了3700多萬(wàn)支新冠疫苗。(財(cái)富中文網(wǎng))
譯者:Agatha
最重要的兩家國(guó)際金融機(jī)構(gòu)稱,,非洲需要大約120億美元才能為足夠多的人接種疫苗,,遏制新冠肺炎在非洲大陸的傳播,。
世界銀行和國(guó)際貨幣基金會(huì)的一份新報(bào)告也指出,G20國(guó)家作為全球最富有的國(guó)家,,應(yīng)將貧困國(guó)家的債務(wù)延期至年底,。
該報(bào)告稱,非洲所需的抗疫資金數(shù)額,,與參與G20債務(wù)償還暫停計(jì)劃的45個(gè)最貧窮國(guó)家已經(jīng)延長(zhǎng)還款的官方債務(wù)償還總額相同,。
而在發(fā)展中國(guó)家廣泛使用的阿斯利康疫苗遭遇了持續(xù)的障礙,這可能限制其在貧窮國(guó)家繼續(xù)推廣,。
《華爾街日?qǐng)?bào)》周二報(bào)道,,牛津大學(xué)暫停了其聯(lián)合開(kāi)發(fā)的阿斯利康疫苗在英國(guó)進(jìn)行的小樣本臨床試驗(yàn),因?yàn)樵撗芯可婕皟和颓嗌倌?,暫停原因是?dān)心血栓問(wèn)題,。
牛津大學(xué)的一位發(fā)言人告訴《華爾街日?qǐng)?bào)》,試驗(yàn)本身沒(méi)有出現(xiàn)安全問(wèn)題,,但對(duì)血栓問(wèn)題的廣泛擔(dān)憂引發(fā)了英國(guó)和歐洲進(jìn)一步的監(jiān)管審查,。
美國(guó)等富裕國(guó)家一直致力于為本國(guó)民眾接種疫苗,但公共衛(wèi)生官員警告說(shuō),,在發(fā)展中國(guó)家為大多數(shù)公民接種疫苗之前,,疫情仍將繼續(xù)。
世界衛(wèi)生組織稱,,非洲國(guó)家接種新冠肺炎疫苗的時(shí)間比世界其他地區(qū)晚得多,,而且數(shù)量有限。目前非洲只有不到10家疫苗制造商,,僅分布在非洲大陸54個(gè)國(guó)家中的5個(gè):埃及,、摩洛哥、塞內(nèi)加爾,、南非和突尼斯,。
許多非洲國(guó)家已簽署協(xié)議,接受由全球疫苗免疫聯(lián)盟Gavi和世衛(wèi)組織領(lǐng)導(dǎo)的新冠肺炎疫苗實(shí)施計(jì)劃(Covax)提供的疫苗,。截至公布之日,該計(jì)劃已向簽署了項(xiàng)目的90個(gè)發(fā)展中國(guó)家運(yùn)送了3700多萬(wàn)支新冠疫苗,。(財(cái)富中文網(wǎng))
譯者:Agatha
Africa needs around $12 billion to vaccinate enough people to contain the spread of COVID-19 on the continent, according to the two major global financial institutions.
A new paper from the World Bank and the International Monetary Fund also said the world’s richest countries, the G20, should extend a debt moratorium for poorer countries until the end of the year.
The paper said the amount of money needed by Africa to prevent transmission of the virus is the same as the total amount of official debt service payments already deferred by 45 of the poorest countries participating in the G20’s Debt Service Suspension Initiative.
AstraZeneca’s vaccine, which has been widely distributed to developing countries, continues to face obstacles that could limit its rollout in poorer nations.
The University of Oxford halted trials of the AstraZeneca vaccine it codeveloped in a small U.K.-based study involving children and teenagers over concerns about blood clotting, the Wall Street Journal reported Tuesday.
No safety issues arose in the trial itself, but wider concerns about blood clotting have triggered further regulatory reviews in the U.K. and Europe, an Oxford spokesperson told the Journal.
Rich countries like the U.S. have focused on vaccinating their own populations, but public health officials warn that the pandemic will continue until developing countries vaccinate a majority of their citizens.
African countries received COVID vaccines much later than the rest of the world and in limited quantities, according to the World Health Organization. There are fewer than 10 African vaccine manufacturers, which are located in only five countries of the 54 on the continent: Egypt, Morocco, Senegal, South Africa, and Tunisia.
Many African countries have signed up to receive vaccines from the Covax effort led by Gavi, the Vaccine Alliance and the WHO. Covax has shipped more than 37 million COVID-19 vaccines to 90 developing countries in its program as of publication.